Praxis Stock Target Raised Amid Analyst Divergence
Wedbush raised Praxis Precision Medicines' price target to $95 on Jan. 12, maintaining an Underperform rating despite a recent $621M offering. Wall Street consensus remains Strong Buy.
Topic
Latest reporting and analysis tagged with biopharmaceutical.
Wedbush raised Praxis Precision Medicines' price target to $95 on Jan. 12, maintaining an Underperform rating despite a recent $621M offering. Wall Street consensus remains Strong Buy.
Wolfe Research downgraded Kymera Therapeutics to Peer Perform on January 6, removing its $92 price target, while BTIG and Citigroup maintained Buy ratings. The stock had gained over 28% in three months, with Wall Street anticipating further growth.
Edgewise Therapeutics shares rose 3% on January 13 after outlining 2026 priorities, including key drug trial milestones. Analysts maintain positive ratings.